Gail H. Cassell, Ph.D., D.Sc. (hon), is Visiting Professor, Department of Global Health and Social Medicine, Harvard Medical School, and Vice President of TB Drug Development of the not-for-profit Infectious Disease Research Institute, Seattle. Dr. Cassell has recently retired as Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, Indiana. In this capacity, among other things, she was responsible for initiating and leading the not-for-profit Lilly TB Drug Discovery Initiative launched in 2007. In 2003, she was one of two individuals at Lilly who initiated and developed the Lilly Multidrug Resistant Tuberculosis Partnership. The partnership has resulted in company support to date of $135 million dollars and is the largest philanthropic effort in Lilly’s 135 year history. The partnership now involves over 20 partners, including WHO and CDC. She is the former Vice President of Infectious Diseases, Drug Discovery, and Clinical Development of Lilly, where she led the programs of a recently FDA approved hepatitis C protease inhibitor from the discovery phase to clinical candidate and the development of a new class of antibiotics from clinical development to product decision. Prior to moving to Lilly in 1997, Dr. Cassell was the former Charles H. McCauley Professor and Chairman of the Department of Microbiology at the University of Alabama Schools of Medicine and Dentistry at Birmingham, a department which ranked first in research funding from NIH during the decade of her leadership. She obtained her B.S. from the University of Alabama in Tuscaloosa and in 1993 was selected by that institution as one of the top 31 female graduates of the 20th century. She obtained her Ph.D. in Microbiology from the University of Alabama at Birmingham and was selected as its 2003 Distinguished Alumnus. She is a past President of the American Society for Microbiology [the oldest and single largest life sciences organization with a membership of over 42,000 (over 20 percent international members)]. She was named to the original Board of Scientific Councilors of the Center for Infectious Diseases, Centers for Disease Control (CDC) and served as Chair of the Board. She has served on the Advisory Board of the Director of NIH, the Director of the CDC, and the Secretary of Health and Human Services Advisory Council of Public Health Preparedness, the FDA’s Science Board, the Advisory Committee to the Commissioner. Currently she is a member of the NIH Science Management Board, the newly appointed “NIH board of Trustees”, and the Advisory Council of the Fogarty International Center of NIH. Since 1996, she has been a member of the U.S.-Japan Cooperative Medical Science Program responsible for advising the respective governments on joint research agendas, (U.S. State Department/Japan Ministry of Foreign Affairs). She was instrumental in establishment of the U.S./Russia Cooperative Medical Sciences and Training Program under the Bilateral Presidential Commission in 2009 which represents a collaboration involving NIH, the US National Academy of Sciences, the IOM, the Russian Academy of Sciences, and the Russian Academy of Medical Sciences. She has served on several editorial boards of scientific journals and has authored over 350 articles and book chapters. Dr. Cassell has received national and international awards for her research in infectious diseases, including two honorary degrees, the CDC Honor Award in Public Health for exceptional leadership and contributions in the development and implementation of CDC’s Emerging Infectious Disease Plan 1997 and a Citation from the FDA Commissioner for her role as Chair of the review of science and technology at the FDA and the Report FDA: Science and Mission at Risk 2008, and the Emmy Klineberger-Nobel Award in 2008 by the International Organization for Mycoplasmology for outstanding and sustained research contributions to the field of mycoplasmology. She is a member of the IOM of the NAS and has recently completed a second 3-year term on the IOM Council, the governing board. She was elected in 2011 to membership on the U.S Council of Foreign Relations and appointed by the Secretary of the Department of Health and Human Services as a member of the CDC Advisory Committee on Tuberculosis Elimination. Dr. Cassell has been intimately involved in establishment of science policy and legislation related to biomedical research and public health. For nine years she was chairman of the Public and Scientific Affairs Board of the American Society for Microbiology; has served as an advisor on infectious diseases and indirect costs of research to the White House Office of Science and Technology Policy, and has been an invited participant in numerous Congressional hearings and briefings related to infectious diseases, anti-microbial resistance, and biomedical research. She has served two terms on the LCME, the accrediting body for U.S. medical schools as well as other national committees involved in establishing policies in training in the biomedical sciences. She is an Emeritus Member of the Board of Research!America and a former member and Chair of the Board of Directors of the Burroughs Wellcome Fund. She has recently completed terms on the Leadership Council of the School of Public Health of Harvard University, the Executive Committee of Columbia University Medical Center Board of Visitors, and the Johns Hopkins School of Nursing. Currently she is a member of the Morehouse School of Medicine Board of Trustees, the Advisory Council of the University of North Carolina Gillings School of Global Public Health, the Stakeholders Advisory Committee of the newly established Howard Hughes Kwazulu-Natal Research Institute for Tuberculosis and HIV in Durban, South Africa.